Space infrastructure company Redwire trims quarterly losses, builds order backlog

Space infrastructure company Redwire trims quarterly losses, builds order backlog


Pete Cannito, Redwire Corporation at the New York Stock Exchange, September 8, 2021.

Source: NYSE

Space infrastructure company Redwire reported fourth-quarter results on Wednesday, saying it further trimmed its losses and built its order backlog.

After rising as much as 10% in premarket trading, Redwire stock fell slightly soon after the opening bell.

related investing news

'Light at the end of the tunnel:' Some analysts see improvements ahead for Micron after tough quarter

CNBC Pro

The company brought in $53.7 million in fourth-quarter revenue, up 31% from the same period a year ago. Its total backlog of orders nearly doubled to $465.1 million as of the end of 2022, compared to the end of 2021.

Redwire also trimmed its adjusted EBITDA loss on a quarter-over-quarter basis, to $773,000 from $1.5 million in the third quarter.

“Our financial performance showed improvement on both a sequential and year-over-year basis,” Redwire  CFO Jonathan Baliff said in a statement.

Sign up here to receive weekly editions of CNBC’s Investing in Space newsletter.

The company had $53.3 million in available liquidity at the end of the year, which was a split mix of cash and borrowing capacity.

For 2023, Redwire forecast full year revenue between $220 million to $250 million, up from $160.6 million in 2022 revenue.



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More